Introduction
Dedifferentiated endometrial carcinomas (DDECs) and undifferentiated endometrial carcinomas (UECs) are among the most aggressive histological types of endometrial cancer, with a reported outcome that is worse than that of FIGO grade 3 endometrioid endometrial carcinomas. 1, 2 The undifferentiated component of UEC and the undifferentiated component of DDECs are similar histologically. They consist of a sheet-like proliferation of monomorphic medium-sized cells with no apparent epithelial differentiation histologically, and the tumour cells frequently appear to be discohesive in nature, imparting a rhabdoid morphology in some cases. 3 Immunophenotypically, the undifferentiated component shows significantly diminished to completely absent expression of epithelial markers [i.e. cytokeratins and epithelial membrane antigen (EMA)] and of Mullerian epithelial transcriptional factors, including PAX8 and oestrogen receptor (ER), in contrast to the typically intact expression of these proteins in the corresponding differentiated component of DDEC. Furthermore, the majority of DDECs/UECs are deficient in the expression of mismatch repair (MMR) proteins. We recently identified frequent genomic inactivation of certain core components of switch/sucrose non-fermentable (SWI/SNF) complex proteins that are associated with histological dedifferentiation. 1, 4 More specifically, there were three mutually exclusive patterns of genomic inactivation, resulting in: (i) loss of BRG1 (encoded by SMARCA4) expression; (ii) loss of INI1 (encoded by SMARCB1) expression; or (iii) concurrent losses of ARID1A and ARID1B expression in the undifferentiated component. This is analogous to what is seen in lung carcinoma and sinonasal carcinoma, [5] [6] [7] in which SWI/SNF inactivation has been reported and is associated with undifferentiated histology as well as aggressive clinical behaviour. Therapeutically, there is accumulating preclinical and early clinical evidence to suggest that tumours that are SWI/SNF-deficient may be more responsive to drugs that target chromatin remodelling. [8] [9] [10] Claudin-4 is a transmembrane protein involved in the formation of intercellular tight junctions, which are important in mediating cell adhesion, proliferation, and differentiation. 11, 12 It is expressed in a variety of normal epithelial tissues, and its expression is also seen in many different types of epithelial malignancy. [13] [14] [15] A number of studies have implicated increased claudin-4 expression with decreased survival, particularly in breast cancer and gastric cancer. [16] [17] [18] Overexpression of claudin-4 in breast cancer and gastric cancer cell lines has been shown to increase cell proliferation and migration in vitro. 19, 20 In endometrial cancer, Pan et al. have observed consistent claudin-4 expression in a series of predominantly low-grade endometrioid-type carcinomas (n = 30, with 23 tumours being FIGO grade 1 or 2). 21 Schaefer et al. recently examined claudin-4 expression in a large number of epithelial and mesenchymal malignancies that included SWI/SNF-deficient tumours such as epithelioid sarcoma, INI1-deficient sinonasal carcinoma, and BRG1-deficient small-cell carcinoma hypercalcaemic type of the ovary, and the results suggested a potential use for claudin-4 in differentiating between tumours of epithelial and mesenchymal origin. 22 The study showed that the great majority of sarcomas with epithelioid morphology or SWI/SNF deficiency lack claudin-4 expression, whereas the great majority of undifferentiated carcinomas, including tumours that are SWI/SNF-deficient, show claudin-4 expression. This study examined only one DDEC for which claudin-4 staining was not specifically reported.
To better understand its expression in DDEC/UEC, we examined claudin-4 expression by immunohistochemistry in a series of DDECs/UECs (including both SWI/SNF-deficient and SWI/SNF-proficient tumours) and in a series of high-grade endometrial epithelial and/or mesenchymal neoplasms.
Materials and methods

S T U D Y S A M P L E
This study examined a total of 366 tumours: with 44 UECs/DDECs (24 SWI/SNF-deficient), 50 carcinosarcomas, 164 grade 3 endometrioid carcinomas, 57 serous carcinomas, 20 clear cell carcinomas, and 31 uterine sarcomas (leiomyosarcomas, rhabdomyosarcomas, adenosarcomas, endometrial stromal sarcomas, and undifferentiated uterine sarcomas). These tumours were evaluated in a series of tissue microarrays (TMAs), with each tumour represented in duplicate cores (0.6 mm). Additional cores were used to represent the different components of DDEC (differentiated and undifferentiated components) and carcinosarcoma (carcinomatous and sarcomatous components) in these TMAs. 1 The study was approved by the Institutional Review Board.
I M M U N O H I S T O C H E M I S T R Y
Immunohistochemistry for claudin-4 was performed with clone 3E2C1 (mouse monoclonal; Invitrogen, Carlsbad, CA, USA) at 1:300 dilution in Da Vinci Green diluent at room temperature for 37 min. Slides were then washed and incubated with Mach2 Mousehorseradish peroxidase polymer for 32 min at room temperature, and detected with IP 3,3 0 -diaminobenzidine chromogen for 5 min. Nuclei were counterstained with a 1:10 dilution of CAT haematoxylin, and slides were washed again, air-dried, and coverslipped manually. MMR protein immunohistochemistry was performed with staining scored as previously described. 23 The slides were incubated with MLH1 (Dako, Santa Clara, CA, USA; clone ES05, 1:100), MSH2 (NCL, Wetzlar, Germany; clone 25D12, prediluted), MSH6 (BD Bioscience, San Diego, CA; 44/MSH6, 1:2000), and PMS2 (BD Bioscience; A16-4, 1:100), and processed with the Leica Bond Max platform (Leica Microsystems, Wetzlar, Germany), according to the manufacturer's protocol, with proprietary reagents.
Claudin-4 staining was scored by two pathologists (B.T.C. and C.H.L.), and membranous staining was evaluated. Differences in scoring were further reviewed by the two pathologists to reach a consensus score. This included two cases with discrepant scoring results that crossed the cut-off threshold (for claudin-4 positivity) described below; for these, consensus scores were reached upon further review. Tumour cells were scored on the basis of their staining intensity (0, no staining; 1, weak membranous staining; 2, moderate membranous staining; and 3, strong membranous staining), and the percentage of tumour cells stained was broken down into six increments (0, no staining; 1, <5%; 2, 5-24%; 3, 25-49%; 4, 50-74%; 5, 75-100%). Positive claudin-4 immunostaining was defined by at least weak-intensity staining in >5% of the tumour cells, and this was the same threshold used by a previous study. 22 The different histological components of DDEC and carcinosarcoma were scored separately. The claudin-4 scoring results of UEC/DDEC cases were confirmed on whole sections.
Results
The results of claudin-4 immunohistochemistry are summarised in Table S1 . We studied 44 DDECs/UECs (20 DDECs and 24 UECs), of which 24 were SWI/SNFdeficient. The differentiated components in all DDECs examined were low-grade endometrioid in type and were all positive for claudin-4, most of them showing expression in >75% of tumour cells (Figure 1) . Nearly all SWI/SNF-deficient UECs/DDECs showed a complete absence of claudin-4 expression in the undifferentiated components ( Figure 1A-D) . Only one of 24 SWI/SNFdeficient DDECs/UECs (BRG1-deficient) was positive for claudin-4, and this tumour showed patchy expression (20%) of claudin-4 in the undifferentiated component but diffuse expression in the corresponding differentiated component. In addition, four cases showed very focal expression of claudin-4 in the undifferentiated components (in 1-2% of the tumour cells), and these cases were considered to be negative for claudin-4, as they were well below the 5% cut-off threshold used by the prior and current studies. Whereas claudin-4 expression in SWI/SNF-deficient undifferentiated tumours typically occurred as scattered single-cell staining, and the cells expressing claudin-4 appeared to be morphologically indistinguishable from cells lacking claudin-4 expression, its expression in one case appeared to occur focally in small nests of tumour cells that possessed a greater amount of cytoplasm (Figure 1E,F) . Among the 20 SWI/SNF-proficient DDECs/ UECs, four tumours were positive for claudin-4 expression in the undifferentiated components (ranging from 30% to 80%). With regard to MMR protein expression status, two of 24 (8%) MMR-deficient DDECs/UECs were positive for claudin-4 and three of 19 (16%) MMR-proficient DDECs/UECs were positive for claudin-4 in the undifferentiated components.
Among other high-grade endometrial carcinomas surveyed, claudin-4 expression was observed in 76% of FIGO grade 3 endometrioid carcinomas, 74% of serous carcinomas, and 55% of clear cell carcinomas. Among uterine carcinosarcomas, claudin-4 expression was found in 92% of the cases, but its expression was restricted to only the carcinomatous components in the positive cases, whereas the corresponding sarcomatous components were consistently negative for claudin-4. The extent of claudin-4 expression in the carcinomatous component of uterine carcinosarcoma was, however, highly variable, ranging from 5% to 100%. In uterine adenosarcoma, claudin-4 was expressed in the benign epithelial elements in the tumour, but its expression was consistently absent in the mesenchymal/sarcoma component. No claudin-4 expression was observed in the pure uterine sarcomas (leiomyosarcomas, rhabdomyosarcomas, endometrial stromal sarcomas, and undifferentiated sarcomas) examined (Figure 2 ).
Discussion
We confirmed in this study frequent expression of claudin-4 in several histotypes of endometrial carcinoma, but the percentage of tumours showing claudin-4 expression was variable across the different histotypes. Most notably, for SWI/SNF-deficient DDECs, whereas the low-grade endometrioid carcinoma component consistently showed claudin-4 expression, the corresponding undifferentiated carcinoma component, in the great majority of cases, lacked claudin-4 expression, despite apparent epithelial origin. In addition, all SWI/SNF-deficient UECs examined also lacked claudin-4 expression. Among SWI/SNF-proficient DDECs/UECs, the undifferentiated components, in the majority of cases, also lacked claudin-4 expression. These findings clearly demonstrate that claudin-4 expression is frequently lost in the process of cellular dedifferentiation in endometrial carcinoma, either through core SWI/SNF complex protein inactivation or by other mechanisms that are currently undefined. This observation is in keeping with our proposed mechanism of dedifferentiation in endometrial cancer, whereby a significant perturbation such as genomic inactivation of core SWI/SNF protein(s) prevents Mullerian epithelial differentiation, hence arresting the tumour cells in a primitive cellular state that is reflected histologically and immunophenotypically as an undifferentiated tumour. This phenomenon is best exemplified in the case of SWI/SNF-deficient DDEC, in which the undifferentiated component arises from the typically lowgrade endometrioid component. 1, 4 The genomic inactivation of core SWI/SNF complex proteins only occurs in the undifferentiated component, and it is associated with loss or markedly diminished expression of epithelial markers such as cytokeratins and EMA, and of PAX8 and ER. Although claudin-4 expression overexpression has been implicated as a negative prognostic and a protumorigenic factor in a number of cancer types, we speculate that, in the case of DDEC/UEC, absent or diminished claudin-4 expression primarily reflects the undifferentiated state of the tumour cells, and it is this arrest at a primitive cellular state that underlies the aggressive clinical behaviour of these tumours. Furthermore, a comparable majority of MMR-deficient DDECs/UECs and MMR-proficient DDECs/UECs showed absent claudin-4 expression, suggesting that the absence of claudin-4 expression is not related to the hypermutating nature of MMR-deficient tumours.
In contrast to SWI/SNF-deficient DDECs/UECs, in which the undifferentiated components were consistently negative for claudin-4, the undifferentiated components in a small subset of SWI/SNF-proficient DDECs/UECs were positive for claudin-4. Although the reason underlying this difference is unknown, as the mechanisms of dedifferentiation in these SWI/ SNF-proficient tumours remain undefined, it is plausible that the claudin-4-positive tumours represent very poorly differentiated examples of FIGO grade 3 endometrioid carcinoma that were morphologically inseparable from DDECs/UECs despite centralised review. Further studies are needed to gain insights into the genetic basis underlying the undifferentiated morphology in SWI/SNF-proficient DDECs/UECs.
In addition to DDECs/UECs, other high-grade endometrial carcinomas can also show an absence of claudin-4 expression, with negative claudin-4 staining being seen in~50% of clear cell carcinomas, 25% of serous carcinomas, and 25% of FIGO grade 3 endometrioid carcinomas. The clinical and biological significance of loss of claudin-4 expression in these endometrial carcinomas is unknown. Diagnostically, these findings show that absent claudin-4 expression is not specific to DDEC/UEC. However, as with other epithelial keratin markers and Mullerian epithelial differentiation markers (i.e. ER and PAX8), the finding of diffuse claudin-4 expression in a tumour would argue against the diagnosis of undifferentiated carcinoma, similarly to the presence of diffuse ER, PAX8, pankeratin and/or EMA staining. 24 There was also consistent absence of claudin-4 expression in the sarcomatous components of uterine carcinosarcoma and adenosarcoma, as well as in pure uterine sarcomas such as leiomyosarcoma and endometrial stromal sarcoma.
Schaefer et al. recently reported that 80% of undifferentiated carcinomas, including tumours that were SWI/SNF-deficient, retained claudin-4 expression. 22 This earlier study, however, focused on undifferentiated carcinoma from other anatomical sites (bone and soft tissue, ovary, nose, and sinuses), and the difference in our findings probably reflects biological differences between undifferentiated carcinomas of the endometrium and undifferentiated carcinomas from other sites. However, given that SWI/SNF-deficient DDEC/UEC frequently lacks claudin-4 expression despite the apparent epithelial origin, especially in the case of DDEC, it is clear that the absence of claudin-4 expression cannot be used to infer mesenchymal origin of an endometrial malignancy. On that note, even though BRG1-deficient small-cell carcinoma hypercalcaemic type of the ovary consistently lacks claudin-4 expression, the lack of claudin-4 expression alone does not necessarily indicate a non-epithelial origin of this tumour.
In summary, claudin-4 expression is frequently absent in DDECs/UECs, particularly in cases that are SWI/SNF-deficient, and this further reflects its primitive undifferentiated state. Although the absence of claudin-4 expression in an undifferentiated tumour can be used to support a diagnosis of DDEC/UEC, it is not specific, as claudin-4 expression can be absent in a subset of other high-grade endometrial carcinomas, and correlation with histological and other immunophenotypic features is important.
